I wonder about it acting on a neuron, like the DRG, with the message passed to the brain?
It's definitely fair to say that, generally speaking, women take better care of their health than men. This has been taken to absurd levels onto misogynistic models, but it's still true. It means little more than women are more likely to report such problems. It doesn't even mean they are more likely to notice them, just report them. Because its counterpart is also known: men generally downplay symptoms and functional decline. Sometimes all the way to an early death.I’m not sure I follow here. Who «sees» us, and why would we be trying to please them?
Yes, but it’s also being used very wrong, on everyone, and as the basis for supposedly curative interventions with great potential for harm.
I’m not suggesting that we don’t raise them, just that it is done in a way that is also less open for misinterpretation. Although I guess it could be argued that pseudoscience doesn’t follow logic, so they are going to end up at their favoured conclusion regardless of which starting point we give them..
At least in the transition phase. After that all bets are offSuccessful de-escalations often involve giving one party a way to withdraw from their position without losing face. Maybe, as and when new evidence arrives, the BPS advocates will feel readier to cede some influence if they can say "oh yes, your 'neural hypervigilance' is what we were driving at all along," instead of having to take it as a humiliating defeat.
The conditions that might be most closely analogous are the seronegative autoinflammatory diseases, including psoriasis, Reiter’s syndrome, ankylosing spondylitis, other MHC Class-I associated seronegative arthropathies[21] and Crohn’s disease.
These antibodies may have high affinity for previously encountered microbes and may have undergone affinity maturation in some past immune response but are relevant because they bind with relatively low affinity to what might be called ‘everyday junk’ antigens that may include antigens derived from gut flora, low-level persistent viruses such as Herpes, partially degraded self proteins with post-translational modifications, or possibly normal host signal pathway proteins, such as heat shock proteins and proteasome components, upregulated during immune responses.
Until recently, treatment for ME/CFS has tended to focus on rehabilitative programs that encourage patients to undertake physical exertion of the sort that triggers symptoms.
ME/CFS has a variable course. Spontaneous improvement or even resolution may occur, chiefly with onset before the age of 20[20]. Otherwise, it is a long-term fluctuating illness, in some cases with progressive deterioration. Adult-onset illness mostly never fully resolves.
And things look similar with long COVID, with resolution continuing as long as patients are followed https://s4me.info/threads/looking-f...vid-in-year-one-and-beyond.44229/#post-610364.The case rate for provisional post-infective fatigue syndrome was
35% (87/250) at six weeks,
27% (67/250) at three months,
12% (29/250) at six months, and
9% (22/250) at 12 months.
Relatively short-term post-viral fatigue, lasting a matter of months, is also common for a number of infections, notably EBV, and diagnostic boundaries are uncertain.
While reading up on MAIT cells I saw that they recognise vitamin B compounds. Could one reason that some of us respond well to doses of B 12 or B complexes be nothing to do with “energy” but that we’re giving MAIT cells something else to be interested in so distract some from their roles in this feedback loop for a bit?
Would your proposed mechanism predict higher prevalence of those conditions in relatives of people with ME/CFS @Jonathan Edwards ?
First, there’s the issue of resolution in the early post-viral/post-infectious years. ME/CFS can now be diagnosed at 3 months post-onset.
Unfortunately I am not able to read this paper indepth but I was wondering whether the mechanism suggested provides an explanation for delayed PEM?
Is this building up from three repeated, notable findings that are unique (?) in combination and as yet unexplained?The paper said:This proposed mechanism could explain why the illness resembles post-infective T cell-mediated autoinflammatory syndromes in age of onset and time course but has a female preponderance similar to autoantibody-mediated disease.
The only hard data I have seen on this is from prospective studies of mono (and Q-fever and Ross River Virus for the Dubbo study) and that appears to show a steady decay curve rather than symptoms starting erratically after a delay. Though other infective and non-infective triggers may have a different pattern.There is no clear time relation between infective illness and onset of ME/CFS, which may be immediate or delayed for weeks or months in patient reports
That's very interesting. Are you suggesting for this model that ME/CFS is basically a single mechanism with numerous ways in?Antibody responses to a range of microbial antigens would not be expected to manifest as the same clinical syndrome; in autoantibody-mediated disease, different antibody specificities are reflected in different clinical syndromes.
How confident are you that the various quite subtle findings are reliable rather than unreliable (e.g. due to publication bias)? I don't have an opinion, but I think the question is worth asking when there are no strong results.Nevertheless, all these findings tend to point to a broad shift in B cell function rather than a single antigen-specific adaptive response.
There was no reference for this - can you say more?An ME/CFS-like illness has been reported after exposure to acetylcholinesterase inhibitors.
I had the impression that the plasma cytokine signature paper finding was post hoc, as well as not being a large effect.
Is this building up from three repeated, notable findings that are unique (?) in combination and as yet unexplained?
The only hard data I have seen on this is from prospective studies of mono (and Q-fever and Ross River Virus for the Dubbo study) and that appears to show a steady decay curve rather than symptoms starting erratically after a delay.
That's very interesting. Are you suggesting for this model that ME/CFS is basically a single mechanism with numerous ways in?
How confident are you that the various quite subtle findings are reliable rather than unreliable
I had thought the mechanism was sickness response/behaviour resulting from cytokines acting directly and on the brain. @Hutan gave the examples of IFN alpha and gamma when administered. Is this just speculative.?
There was no reference for this - can you say more?
I had the impression that the plasma cytokine signature paper finding was post hoc, as well as not being a large effect.
You’re right. Looks like it’s vitamin B2 (riboflavin) and B9 (folic acid) metabolites. May be relevant for them but was just a passing thought really.I don't think it is to do with B12 is it? I think it is another B.
There's this study, but it was studying CF, not CFS: Chronic fatigue and organophosphate pesticides in sheep farming: a retrospective study amongst people reporting to a UK pharmacovigilance scheme (2003, Ann Occup Hyg)You would have to ask Margaret Mar who got her ME/CFS from a sheep dip. She is a peer of the realm so her evidence does not require a formal citation!
I'm assuming the RA/Lupus/omplement example also ties in with your point about making all the details fit.The proposal is that it may all make sense if we insist on making all the details fit. That is how we came to an answer for RA.
I don't think they looked at onset time to fatigue, but then I think there is a lot more to be gained from prospective studies if done better. In particular, can we distinguish those that go on to have ME/CFS from those that don't at an early stage?The problem here is that Dubbo is mostly about people who will turn out not to have ME/CFS but PVF. I don't know whether they assessed time delay to onset of fatigue. My information on this comes partly from asking individuals but mostly from the poll I did here.
[re "are you proposing a single mechanism]Yes.
Given its role in ME/CFS, that would be helpful.I just think that maybe malaise needs to be looked at more carefully.
Ha! I do remember her mentioning it publicly now.You would have to ask Margaret Mar who got her ME/CFS from a sheep dip. She is a peer of the realm so her evidence does not require a formal citation!
https://s4me.info/threads/was-there-a-gap-between-trigger-and-onset-of-your-me-cfs.40505/Do you (or does anyone) have a link to that poll of fatigue delay?
Many researchers have argued that the wide variation of presentation is due to it being a collection of different illnesses. What would be this model's explanation for the variation?
Here's the Dubbo Study Results:The problem here is that Dubbo is mostly about people who will turn out not to have ME/CFS but PVF. I don't know whether they assessed time delay to onset of fatigue.
People were assessed against the Fukuda CFS criteria at 6 months by clinicians familiar with (ME)/CFS - 28/29 of the people with the 'post-infective fatigue syndrome phenotype' were assessed as having CFS. We have seen that PEM is hard to diagnose. I think it's reasonable to assume that the Dubbo study tells us a lot about ME/CFS.Results
Prolonged illness characterised by disabling fatigue, musculoskeletal pain, neurocognitive difficulties, and mood disturbance was evident in 29 (12%) of 253 participants at six months, of whom 28 (11%) met the diagnostic criteria for chronic fatigue syndrome. This post-infective fatigue syndrome phenotype was stereotyped and occurred at a similar incidence after each infection. The syndrome was predicted largely by the severity of the acute illness rather than by demographic, psychological, or microbiological factors.
The 94 family practitioners and all four diagnostic pathology laboratories that serve the region cooperated to provide us with coded reports of all IgM positive serological results indicating acute Epstein-Barr virus, Q fever, or Ross River virus infections. Patients aged 16 years or over, who provided written informed consent, were enrolled through their family doctor. We excluded patients who had symptoms present for more than six weeks or reported pre-existing medical disorders or drug use likely to be associated with prolonged fatigue. After the baseline assessment, we followed up participants at three weeks, six weeks, and three months, after which we further evaluated a matched case-control series (see below). We reviewed all enrolled participants again at 12 months.
It's a bit hard to tell. There was a gap between the test for the acute disease and the baseline assessment, with the serological results coming through, the person being enrolled in the study and arrangements being made for the baseline assessment in between. There's an indication that the researchers tried to get the baseline assessment done within six weeks of acute illness onset. The requirement that people classified as having PIFS had physical symptoms at all times from the baseline assessment to 3 months, suggests that the researchers didn't really see participants having a delay in the onset of symptoms after the baseline assessment).We classified participants as provisional cases of post-infective fatigue syndrome if their SOMA scores at all time points up to and including three months exceeded the established threshold score.16 We invited these cases, and control participants matched by age and sex who had recovered promptly from the same infection, at six months for a medical interview, examination by a physician (AL), and laboratory investigation to exclude alternative medical explanations for ongoing symptoms...Where appropriate, AL and IH diagnosed the chronic fatigue syndrome (termed here confirmed post-infective fatigue syndrome) by consensus at six months after the onset of symptoms, according to the international diagnostic criteria.1